文献速递慢阻肺

TREM-2表达与COPD中M2样巨噬细胞活性及疾病严重程度相关

Triggering Receptor Expressed on Myeloid Cells-2 Expression Tracks With M2-Like Macrophage Activity and Disease Severity in COPD.
PubMed 文献 · Chest · 2017-10-07

该研究检测COPD患者肺组织中TREM-2与TREM-1的表达,发现GOLD IV期COPD肺组织TREM2(而非TREM1)mRNA水平较非COPD肺组织升高,TREM-2蛋白亦增加并定位于巨噬细胞。在风险及GOLD I-IV期患者中,TREM2/TREM1 mRNA比值与CHIT1 mRNA升高及FEV1、FEV1/FVC下降相关。

要点

  • COPD肺组织中TREM-2表达增加,TREM-1未见增加。
  • TREM-2定位于CD14+、CD68+和CCR2+巨噬细胞。
  • TREM2/TREM1比值与FEV1及FEV1/FVC下降相关。

核心结论

  • COPD肺巨噬细胞中TREM-2表达增加,尤其与TREM-1相比。
  • TREM-2水平及TREM-2/TREM-1比值提示COPD肺组织M2活化。
  • TREM-2可能有助于指导针对2型免疫反应的治疗。

研究设计与样本

  • 获取GOLD IV期COPD肺移植受者肺组织(n=16)。
  • 获取非移植供体肺组织(n=7)。
  • 获取有风险或GOLD I至IV期患者切除肺组织(n=55)。
  • 评估TREM-2和TREM-1 mRNA、蛋白表达及其他2型免疫反应标志物。

主要发现

  • GOLD IV期COPD肺组织TREM2(而非TREM1)mRNA水平较非COPD肺组织升高。
  • TREM2 mRNA与DAP12、CD68、CD206和CHIT1共表达。
  • COPD肺组织TREM-2蛋白增加,流式细胞术显示定位于CD14+巨噬细胞,免疫染色显示定位于CD68+和CCR2+巨噬细胞。
  • 风险及GOLD I至IV期患者肺样本中TREM2(而非TREM1)mRNA水平升高。
  • TREM2/TREM1 mRNA比值与CHIT1 mRNA升高及FEV1和FEV1/FVC下降相关。

临床怎么用

  • TREM-2水平及TREM-2/TREM-1比值可用于提示COPD肺组织M2活化。
  • 上述指标可能帮助指导针对2型免疫反应的治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cell and animal models show a key role for Triggering Receptor Expressed on Myeloid Cells (TREM)-2 in chronic airway disease after viral infection, but comparable evidence in humans still needs to be established. METHODS: Lung tissue samples were obtained from lung transplant recipients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV COPD (n = 16), nontransplantable donor lung tissues (n = 7), and resected lung tissues from patients at risk or with GOLD stage I through IV (n = 55) and were assessed for TREM-2 and TREM-1 messenger RNA (mRNA), protein expression, and other markers of a type 2 immune response. RESULTS: TREM2 (but not TREM1) mRNA levels were increased in GOLD stage IV COPD lung tissues compared with non-COPD lung tissues. TREM2 mRNA was coexpressed with its signaling molecule DAP12 and the macrophage marker CD68 and M2-macrophage markers CD206 and CHIT1. TREM-2 protein was also increased in COPD lung tissues and was localized to CD14+ macrophages by flow cytometry and CD68+ and CCR2+ macrophages by tissue immunostaining. In lung samples from patients at risk and with GOLD stage I through IV COPD, TREM2 but not TREM1 mRNA levels were also increased, and the ratio of TREM2/TREM1 mRNA levels was associated with increases in CHIT1 mRNA and decreases in FEV1 and FEV1/FVC. CONCLUSIONS: TREM-2 expression is increased in lung macrophages in COPD, particularly in comparison with TREM-1. Therefore, TREM-2 levels and the ratio of TREM-2/TREM-1 signifies M2 activation in COPD lung tissues and may help to guide therapeutics directed against the type 2 immune response in patients with this disease.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Byers DE, Wu K, Dang-Vu G, et al. Triggering Receptor Expressed on Myeloid Cells-2 Expression Tracks With M2-Like Macrophage Activity and Disease Severity in COPD. Chest. 2017. PMID: 29017955. doi:10.1016/j.chest.2017.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。